Status:
COMPLETED
Role of Montelukast in Modulation of Response to Sepsis in Preterm Infants
Lead Sponsor:
Mansoura University Children Hospital
Conditions:
Neonatal Sepsis
Eligibility:
All Genders
1-30 years
Phase:
PHASE1
Brief Summary
The investigators will conduct this study to explore the role of Montelukast in treatment of neonatal sepsis and whether it has an effect on inflammatory markers, the duration of antibiotic use, or on...
Detailed Description
Since inflammatory mediators play a crucial role in the pathophysiology of sepsis so anti-inflammatory treatment, Montelukast, could be a beneficial therapy. The investigators will conduct this pilot,...
Eligibility Criteria
Inclusion
- 1\. Infants with gestational age from 34 weeks to less than 37 weeks (late preterm) and weighted more than 1.5 Kg with clinical evidence of neonatal sepsis (Wynn 2016).
Exclusion
- \- 1. Infants presented initially with septic shock, multi-organ dysfunction syndrome (MODS), disseminated intravascular coagulopathy.
- 2\. Infants with major congenital malformations 3. Infants with chromosomal aberrations 4. Postoperative patients.
Key Trial Info
Start Date :
July 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 10 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04474327
Start Date
July 24 2020
End Date
February 10 2021
Last Update
February 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University Childran Hospital
Al Mansurah, Dakahlia Governorate, Egypt, 35116